


MicroBiopharm Japan

Company Profile

MicroBiopharm Japan (MBJ) specializes in comprehensive microbial technologies and has 80 years of experience. We utilize microorganisms to support our partners in various stages of research, development, and commercial production.



## History/Our Sites

#### History

- **1941** Started the production of Acetone and Butanol by fermentation at Showa Nosan Kako Co., Ltd. (currently Mercian Corporation) Yatsushiro plant (Business started)
- **1981** Started the production of the injectable Aclarubicin
- **1988** Started the production of Daunorubicin Started the production of injectable Pirarubicin
- **1989** Started the production of Doxorubicin
- **1994** Started the production of Calcitriol
- 2007 Started the production of Epirubicin
- 2010 Started the production of 25-Hydroxyvitamin D<sub>3</sub>
- 2011 MBJ was founded and we started the business by the succession of the Pharmaceuticals & Chemicals Division of Mercian Corporation.
- 2016 Operation start up at Kiyosu plant (Protein production CDMO), acquired from Astellas Pharma Inc.
- **2018** Completed construction of New Manufacturing Building in Iwata plant
- 2019 Completed construction of New Manufacturing Building in Kiyosu plant
- **2020** Completed construction of New Manufacturing Building in Yatsushiro plant
- 2021 Investment funds managed by T Capital Partners Co., Ltd. became our shareholder.

#### Sites and Facilities

#### Head Office (Tokyo)



#### **Kiyosu Plant**



Plant • Protein production

R&D •Basic research •Fermentation and synthesis

Audit experience ·Local authority (PMDA)

#### **Iwata Plant**



#### **Yatsushiro Plant**



•Mid scale fermentation (Up to 30 kL)

Plant

•Pilot plant

•Fermentation and synthesis

Audit experience ·Local authority / FDA etc.

Plant -Large scale fermentation (Up to 100 kL) -Chemical synthesis and purification facility

Audit experience ·Local authority / FDA etc.

# Our Products/Service

#### Commercial

Category	Compound name	Specification	Structure	Category	Compound name	Specification	Structure
	Daunorubicin Hydrochloride	In-house		Osteoporosis	Calcitriol	USP, JP, In-house	иночет Сон
Anti	Doxorubicin Hydrochloride	USP, JP, EP		Rare Amino acid	<i>cis</i> -5-Hydroxy-L- Pipecolinic acid	In-house	HO (S) N H CO <sub>2</sub> H
cancer drug Anthracycline	Epirubicin Hydrochloride	JP, EP		Immuno suppressant	Rapamycin (Sirolimus) Crude	In-house	
* API production on	Pirarubicin*	JP					

\* API production and formulation

Fermentation products
 Fermentation + Synthesis products
 Bioconversion products


### **Under Development & CDMO**

Category	Compound name	Specification	Structure	Category	Compound name	Specification	Structure
	<b>2</b> 5-Hydroxy-Vitamin D <sub>3</sub>	Pharmaceutical	иом страна стр	СДМО	Josamycin	Antibiotics	ри , сно , со ,
Under	Ansamitocin P-3	Payload for ADC etc.			E-poly-L-Lysine	Food additive	
Development	Maytansinol	Payload for ADC etc.	MeO HeO HeO HeO HeO HeO HeO HeO H	* There are several other CDMO projects * Under development of ADC site-specific conjugation technology Service			
	<b>Everolimus</b>	Pharmaceutical		Plasmid	and starting opera	t microorganisms use fermentation ar	rocesses nd purification facilities,

Fermentation products Fermentation + Synthesis products Bioconversion products


# Our Collaboration Scheme

MBJ provides collaboration services at each stage.



### 1 Drug Discovery Support

Hydroxylation of various lead compounds with P450 library




Production of new derivatives difficult by chemical synthesis

Improvement of physical properties

#### 2 Process Optimization • Process Development

2-1. Process optimization and robustness improvement based on QbD (Quality by Design)




Assemble design space by multivariate analysis




Process development for commercial use
Development of recombinant protein manufacturing processes
Scalable processes for plasmid DNA manufacturing
Efficient production of compounds which are difficult to synthesis chemically


2-2. Optimization of manufacturing processes




2-3. Development of one step bioconversion for obtaining hydroxylated compound by introducing P450 gene to MBJ original strain



#### **3** Commercial Manufacturing







 $\mathbf{i}$ 

Commercial production under optimized conditions

# There are multiple commercial and development projects

Low molecular compound (Fermentation/Bioconversion + Synthesis), protein, plasmid and peptide etc.

# Equipment List

#### **Research & Development**

			R&D in Kiyosu	R&D in Iwata
Basic research/       Equipment list of R&D         Pilot production       (Investigational drug GMP/GILSP)		For	Basic research •Explore microorganism •Seed culture •Develop manufacturing process	Optimization •Pilot manufacturing •Establishment of product specification
	Fermentation tank	Lab testing Up to 30 L	From lab testing to pilot production Up to 5 kL	
		Equipment	Centrifuge TFF membrane Homogenizer Up to 45 L column Isolator $(0.1 \ \mu g/m^3)$ Freeze dryer Droplet generator Cell sorter	Centrifuge Filter press TFF membrane Up to 1,000 L column Thin film evaporator Reactors



#### **Plants**

Manufacturing of low molecular compound

Fermentation & Bioconversion (GMP/GILSP)



	Iwata Plant	Yatsushiro Plant
For	Mid scale fermentation (Pilot scale production, manufacturing small scale high value-added products)	Large scale fermentation (Synthesis, purification, bioconversion of highly potent compounds)
Fermentation tank	Up to 30 kL	Up to 100 kL
Equipment	Filter press TFF membrane Reactors Isolator (handle highly potent) Balance enclosure	TFF membrane Up to 40 kL column Thin film evaporator Spray dryer Reactors Shelf dryer Handle highly potent (0.2 µg/m

		Kiyosu Plant
Manufacturing of biopharmaceuticalProtein, Peptide & Plasmid etc.(GMP/GILSP)	For	Production of recombinant protein API, intermediate and peptide (Enzyme, hormone, cytokine, small molecule antibody etc.)
	Fermentation tank	Stainless up to 2 kL
	Equipment	Centrifuge TFF membrane Homogenizer Up to 45 L column Freeze dryer



# Bio Pilot at Kiyosu

- Workshop for manufacturing and development of plasmid DNA using recombinant microorganisms
- GMP/Non-GMP

	Bio Pilot
Objective	Plasmid DNA for gene therapy and API
Main equipment	•Single-use fermentation tank (300 L) •Single-use chromatography •TFF membrane



## **Containment Workshops at Yatsushiro**

- 40 + years of experience in the production of highly potent APIs
- Inspected by the FDA
- Capable of handling highly potent compounds (Reactors up to 200 L/Category 4, 5)

Category	4 5 (OEL 0.1 μg/m³)
Cleanness (USA Fed.Std.209E)	100,000
Main equipment	<ul> <li>•Reactor: 200 L (GL)</li> <li>•Crystallization tank: up to 320 L (SUS)</li> <li>•Purification column</li> <li>•Filter, Concentrator (EVAPOR),</li> <li>Dryer (Shelf type and Hastelloy filter type)</li> </ul>





# MicroBiopharm Japan Co., Ltd.

1-3-1 Kyobashi, Chuo-ku, Tokyo, 104-0031 JAPAN Tel.+81-3-6265-1761 Fax.+81-3-6265-1768 https://www.microbiopharm.com